Irritable bowel syndrome (IBS) often includes ongoing abdominal pain that can be hard to explain and even harder to predict. For some people, standard approaches like diet changes, antispasmodics, or constipation and diarrhea medicines do not fully address pain. In those cases, clinicians may discuss certain antidepressants as “gut-brain axis meds” (also called neuromodulators) because they can change how the gut and nervous system communicate, not because IBS is “all in the mind.”
How “gut-brain axis” medicines can reduce IBS pain
IBS is considered a disorder of gut-brain interaction, meaning symptoms can be linked to changes in gut movement, gut sensitivity, immune signaling, the gut microbiome, and how the central nervous system processes gut sensations. Pain can be amplified by “visceral hypersensitivity” (extra-sensitive nerves in the digestive tract), along with stress, poor sleep, and repeated symptom flares. This helps explain why treatments that affect nerve signaling sometimes reduce IBS pain even when they are not designed as gut-specific drugs. [1]
In IBS care, antidepressants are sometimes used at lower doses than those used for depression, with the goal of dialing down pain signaling and improving overall symptom control over time. These medications can take a few weeks to noticeably help, and side effects can happen, so the decision often comes down to balancing possible benefits (less pain, fewer “bad gut days”) with tolerability and a person’s bowel pattern (more constipation, more diarrhea, or mixed). NHS patient guidance also notes that medicines such as amitriptyline (a tricyclic antidepressant) and citalopram (a selective serotonin reuptake inhibitor) may be used for IBS symptoms and may take several weeks to work. [2]
TCA for IBS vs SSRI IBS: what the evidence suggests
Tricyclic antidepressants (TCAs) are the most commonly discussed antidepressants for IBS pain. A TCA for IBS may be offered because this class has evidence for improving global IBS symptoms (including pain), and major U.S. gastroenterology guidance supports their use. The American College of Gastroenterology recommends TCAs for global IBS symptoms, and the American Gastroenterological Association suggests TCAs while suggesting against selective serotonin reuptake inhibitors (SSRIs) for IBS overall symptoms and pain. [3] Common examples include amitriptyline IBS and nortriptyline IBS (both TCAs). TCAs can also slow gut transit in some people, which is one reason clinicians may be cautious about constipation.
SSRIs (selective serotonin reuptake inhibitors), such as sertraline, fluoxetine, or citalopram, are generally less consistent for IBS pain in research, even though they are very effective for depression and some anxiety disorders. That said, not all guidelines interpret the evidence the same way. The British Society of Gastroenterology notes TCAs as an effective second-line option for global symptoms and abdominal pain, and suggests SSRIs may help global symptoms for some people, but with weaker evidence. [4] This is one reason the “TCA vs SSRI” question can sound simple but feel complicated in real life.
Recent clinical trial data also supports TCAs for IBS pain and overall severity. In the ATLANTIS randomized trial (published 2023), low-dose amitriptyline led to greater improvement in IBS severity scores than placebo over 6 months, although some participants stopped treatment due to side effects. [5]
When comparing antidepressants for IBS pain, topics clinicians often review include:
- the main symptom goal (pain relief, bowel habit changes, sleep)
- constipation-leaning vs diarrhea-leaning IBS patterns
- side effect concerns and other medications (to reduce interaction risks)
- mental health history, since treating anxiety or depression can also improve quality of life
Tracking pain trends in Aidy can make these conversations more specific over time, especially when patterns are hard to spot day to day.